Recent studies have highlighted promising avenues for future exploration; early-phase data have demonstrated the efficacy of selumetinib, an MEK inhibitor, in reducing the size of inoperable plexiform neurofibromas in children with NF1. Here, MAP2K7 is linked to plexiform neurofibroma.